Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Bausch Health Companies Inc.
Bausch Health Companies Inc. News
Jul 10, 2025 - accessnewswire.com
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
Jul 10, 2025 - accessnewswire.com
Bausch Health Appoints New Chief Accounting Officer
Jul 9, 2025 - accessnewswire.com
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
Jul 7, 2025 - accessnewswire.com
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Bausch Health Companies Inc. Quantitative Score

About Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Bausch Health Companies Inc. Financials
Table Compare
Compare BHC metrics with: | |||
---|---|---|---|
Earnings & Growth | BHC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BHC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BHC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BHC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Bausch Health Companies Inc. Income
Bausch Health Companies Inc. Balance Sheet
Bausch Health Companies Inc. Cash Flow
Bausch Health Companies Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Bausch Health Companies Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 1.2800 |
Payment Date | Dividend | Frequency |
---|---|---|
2010-12-22 | 1 | Quarterly |
2010-10-04 | 0.095 | Quarterly |
2010-07-05 | 0.095 | Quarterly |
2010-04-05 | 0.09 | Quarterly |
2010-01-04 | 0.09 | Quarterly |
Historical Market Cap
Shares Outstanding
Bausch Health Companies Inc. Executives
Name | Role |
---|---|
Mr. Thomas J. Appio | Chief Executive Officer & Director |
Ms. Seana Carson | Executive Vice President & General Counsel |
Ms. Aimee J. Lenar | Executive Vice President of US Pharma |
Mr. Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer |
Mr. Mirza Dautbegovic | Executive Vice President & Chief Operating Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Thomas J. Appio | Chief Executive Officer & Director | Male | 1962 | 3.1M |
Ms. Seana Carson | Executive Vice President & General Counsel | Female | 1973 | 1.02M |
Ms. Aimee J. Lenar | Executive Vice President of US Pharma | Female | 929.78K | |
Mr. Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer | Male | 1965 | 740.8K |
Mr. Mirza Dautbegovic | Executive Vice President & Chief Operating Officer | Male | -- |
Bausch Health Companies Inc. Insider Trades
Date | 14 Jul |
Name | LEE STEVEN HYOSIG |
Role | SVP, Controller & CAO |
Transaction | Acquired |
Type | A-Award |
Shares | 27371 |
Date | 14 Jul |
Name | LEE STEVEN HYOSIG |
Role | Officer |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | 30 Jun |
Name | Paulson John |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 9384 |
Date | 30 Jun |
Name | ICAHN BRETT |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 4034 |
Date | 30 Jun |
Name | WECHSLER AMY B |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1032 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
14 Jul | LEE STEVEN HYOSIG | SVP, Controller & CAO | Acquired | A-Award | 27371 |
14 Jul | LEE STEVEN HYOSIG | Officer | Disposed | 0 | |
30 Jun | Paulson John | Director | Acquired | A-Award | 9384 |
30 Jun | ICAHN BRETT | Director | Acquired | A-Award | 4034 |
30 Jun | WECHSLER AMY B | Director | Acquired | A-Award | 1032 |